Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (HROW) on October 5, 2022, reporting an event effective as of September 30, 2022. The filing details a strategic divestiture of a specific business segment.
Key Financial Metrics and Transaction Details
The Company entered into an Asset Purchase Agreement to sell substantially all assets associated with its non-ophthalmology related compounding business. Key financial terms include:
- Upfront Cash Consideration: $6,000,000 paid on October 5, 2022.
- Contingent Consideration: Up to $4,500,000 payable based on revenue milestones achieved during calendar year 2023.
- Total Potential Value: $10,500,000.
- Assets Sold: Intellectual property rights, customer lists, databases, and formulations related to non-ophthalmology compounding.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's overall operations for the period.
Material Changes and Operational Impact
As a result of the transaction:
- The Company divested its non-ophthalmology compounding business to Innovation Compounding Pharmacy, LLC.
- Six employees responsible for sales activities associated with the sold assets were offered employment by the Buyer.
- The Company entered into a transition services agreement to provide ongoing services, such as procuring and dispensing prescription orders, for up to six months following the effective date.
Outlook, Risks, and Contingencies
The Company expects to receive additional consideration contingent upon the Buyer meeting mutually agreed-upon revenue milestones in 2023. The filing notes that the summary is qualified by the full text of the Agreement, which is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.
Key Facts for Investor Verification
- Verify the specific revenue milestones required to trigger the $4,500,000 contingent payment in the full Asset Purchase Agreement.
- Review the upcoming Form 10-Q for the quarter ended September 30, 2022, for the full text of the Agreement and any financial impact analysis.
- Confirm the duration and scope of the transition services agreement to assess ongoing operational obligations.
- Assess the strategic rationale for retaining only the ophthalmology-related compounding business.